Pharmacia year-end results
This article was originally published in The Tan Sheet
Executive Summary
Consumer healthcare sales up 10.6% to $229 mil. in fourth quarter and 13.3% to $829 mil. for the year, "representing a second consecutive year of double-digit sales growth," firm reports Feb. 19. Gains were driven by "strong growth" in Nicorette smoking cessation franchise, which recorded sales increases of 15% in Q4 and 31% for the year. Pharmacia's total sales were flat at $3.74 bil. in the quarter and $13.99 bil. in 2002. On a reported basis, net earnings leapt to $554 mil. in Q4 from $86 mil. the previous year, spurred by one-time gain of $100 mil. from a patent infringement settlement with Allergan, $26 mil. from product licensing rights. Net earnings for 2002 dipped 60.2% to $1.5 bil. Firm's acquisition by Pfizer expected to close in Q1 2003 (1"The Tan Sheet" Jan. 27, 2003, p. 5)...
You may also be interested in...
Pfizer/Pharmacia Consumer Product Divestitures Addressing Overlaps – Exec
Overlapping consumer product categories appear to be delaying U.S. and EU regulatory approval of Pfizer's acquisition of Pharmacia
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.